RRA analysis further identify a set of MSI1-bound genes in G3 MB, including TMEM33, SFNX and HIPK1, as cancer-selective downstream targets for therapeutic drug targeting (i.e., not bound in NSC) (Fig. 4b left panel, Supplementary Fig. 9a). This evidence concerns the gene TMEM33 and cancer.